Locus Biosciences, Inc.

Silver Sponsor

Locus Biosciences is a clinical-stage biotechnology company developing CRISPR-enhanced precision antibacterial products (crPhage™) to address critical unmet medical needs in bacterial infections and microbiome indications in immunology and oncology. The Locus platform combines CRISPR-Cas3, which shreds target DNA within a bacterial cell, with bacteriophage to specifically kill target pathogens while leaving non-target bacteria (i.e., the rest of the patient’s microbiome) unharmed.  Locus has strong backing from partners, having signed a collaboration agreement with Johnson & Johnson worth up to $818 million in milestones and has signed contracts with BARDA (up to $77 million) and with CARB-X (up to $12 million).


GET INVOLVED AT THE

WORLD ANTI-MICROBIAL RESISTANCE CONGRESS

 

To Sponsor Or Exhibit

 


Semen Sen

semen.sen@terrapinn.com
+1 646.619.1793

 

 

To Speak

 


Emma Goaley

emma.goaley@terrapinn.com
+1 646.400.2576

 

 

Press & Media Partnerships

 


Ipek Coskun

ipek.coskun@terrapinn.com
+1 407.421.5818